Company TransCode Therapeutics, Inc.

Equities

RNAZ

US89357L3033

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Quarterly revenue - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 21:00:00 18/06/2024 BST			5-day change	1st Jan Change
1.01 ^USD	-10.62%		-17.89%	-84.68%

05-29	TransCode Therapeutics, Inc. Reports Positive Data from First-In-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138	CI
05-15	TransCode Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Companyâs lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Companyâs pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.

Number of employees: 10

Managers	Title	Age	Since
Thomas Fitzgerald CEO	Chief Executive Officer	73	30/06/18
Zdravka Medarova FOU	Founder	50	31/12/15
Susan Duggan COO	Chief Operating Officer	-	-
Alan Freidman IRC	Investor Relations Contact	-	-
Seth Gregg PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Magda Marquet BRD	Director/Board Member	65	31/12/20
Philippe Calais CHM	Chairman	65	30/09/18
Erik Manting BRD	Director/Board Member	53	19/12/20
Thomas Fitzgerald CEO	Chief Executive Officer	73	30/06/18

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	6,622,053	6,613,562 ( 99.87 %)	0	99.87 %

Name	Equities	%	Valuation
Sabby Management LLC 5.096 %	334,823	5.096 %	594 311 $
Virtu Financial LLC 0.8421 %	55,329	0.8421 %	98 209 $
The Lind Partners LLC 0.4000 %	26,279	0.4000 %	46 645 $
Two Sigma Securities LLC 0.3345 %	21,975	0.3345 %	39 006 $
Tower Research Capital LLC 0.0750 %	4,927	0.0750 %	8 745 $
Robert Dudley 0.0686 %	4,507	0.0686 %	8 000 $
Thomas Fitzgerald 0.0214 %	1,408	0.0214 %	2 499 $
Philippe Calais 0.002435 %	160	0.002435 %	284 $
Wells Fargo Bank NA 0.000076 %	5	0.000076 %	9 $
RBC CMA LLC 0.000015 %	1	0.000015 %	2 $

TransCode Therapeutics, Inc.

6 Liberty Square Suite 2382

02109, Boston

http://www.transcodetherapeutics.com

address TransCode Therapeutics, Inc.(RNAZ)

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.01 USD

Average target price

120 USD

Spread / Average Target

+11,781.19%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
TRANSCODE THERAPEUTICS, INC.	-84.68%	6.69M
VERTEX PHARMACEUTICALS INCORPORATED	+14.84%	121B
REGENERON PHARMACEUTICALS, INC.	+18.31%	112B
ARGENX SE	+4.45%	22.57B
BIONTECH SE	-18.26%	20.82B
GENMAB A/S	-16.84%	16.19B
WUXI APPTEC CO., LTD.	-42.36%	16.17B
BEIGENE, LTD.	-14.23%	16.3B
NEUROCRINE BIOSCIENCES, INC.	-0.68%	13.17B
SAREPTA THERAPEUTICS, INC.	+21.87%	11.11B

Bio Therapeutic Drugs